Today's participants and agenda AGENDA Introduction Todd Interim SURF301 TYRA-300 results Doug Q&A: Perspective of a leading Urologist Gary Todd Harris, PhD Doug Warner, MD Gary Steinberg, MD CEO, TYRA CMO, TYRA Professo

Interim clinical proof-of-concept with

TYRA-300 in mUC (SURF301) October 25, 2024 Exhibit 99.1

Today's participants and agenda

AGENDA Introduction Todd Interim SURF301 TYRA-300 results Doug Q&A: Perspective of a leading Urologist Gary Todd Harris, PhD Doug Warner, MD Gary Steinberg, MD CEO, TYRA CMO, TYRA Professor of Urology, Dept. of Urology, Rush University Medical

Disclaimers We caution you that this

presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our business strategy, research and development plans, the anticipated timing

and phase of development, costs, design and conduct of our ongoing and planned preclinical studies and clinical trials for our product candidates, the timing and likelihood of regulatory filings and approvals for our product candidates, the

potential to develop product candidates and for them to be first-in-class, and the potential safety and therapeutic benefits of our product candidates, our ability to commercialize our product candidates, if approved, the pricing and reimbursement

of our product candidates, if approved, the timing and likelihood of success, plans and objectives of management for future operations, and future results of anticipated product development efforts, are forward-looking statements. In some cases, you

can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend,"

"target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar

expressions. The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved. Actual results may differ from those set forth in this presentation due to the risks and uncertainties

inherent in our business, including, without limitation: interim results of a clinical trial are not necessarily indicative of final results and one or more of the clinical outcomes may materially change as patient enrollment continues, following

more comprehensive reviews of the data, as follow-up on the outcome of any particular patient continues and as more patient or final data becomes available, including the risk that unconfirmed responses may not ultimately result in confirmed

responses to treatment after follow-up evaluations; the potential for proof-of-concept results to fail to result in successful subsequent development of TYRA-300; competitors; unfavorable results from preclinical studies; we may not realize the

benefits (i) associated with orphan drug designation, including that orphan drug exclusivity may not effectively protect a product from competition and that such exclusivity may not be maintained or (ii) from the rare pediatric disease designation,

including potential to receive a Priority Review Voucher (PRV) or derive any value therefrom; regulatory developments in the United States and foreign countries; our ability to obtain and maintain intellectual property protection for our product

candidates and proprietary technologies; and other risks described in our prior filings with the Securities and Exchange Commission (SEC), including under the heading "Risk Factors" in our annual report on Form 10-K and any subsequent

filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances

that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This presentation

also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to

give undue weight to such estimates. In addition, projections, assumptions, and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. These

and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us. we are early in our development efforts, have only recently begun testing TYRA-300 and TYRA-200 for oncology

in clinical trials and the approach we are taking to discover and develop drugs based on our SN P platform is novel and unproven and it may never lead to product candidates that are successful in clinical development or approved products of

commercial value; potential delays in the commencement, enrollment, data readouts, and completion of preclinical studies and clinical trials; results from preclinical studies or early clinical trials not necessarily being predictive of future

results; our dependence on third parties in connection with manufacturing, research and preclinical testing; we may expend our limited resources to pursue a particular product candidate and/or indication and fail to capitalize on product candidates

or indications with greater development or commercial potential; acceptance by the FDA of INDs or of similar regulatory submissions by comparable foreign regulatory authorities for the conduct of clinical trials of TYRA-300 in pediatric

achondroplasia or hypochondroplasia; an accelerated development or approval pathway may not be available for TYRA-300 or other product candidates and any such pathway may not lead to a faster development process; later developments with the FDA may

be inconsistent with the minutes from our prior meetings, including with respect to the design of our planned Phase 2 study of TYRA-300 in ACH; unexpected adverse side effects or inadequate efficacy of our product candidates that may limit their

development, regulatory approval, and/or commercialization; the potential for our programs and prospects to be negatively impacted by developments relating to our competitors, including the results of studies or regulatory determinations relating to

our Forward-looking statements and market data

Our expertise in FGFR biology creates

a differentiated pipeline Discovery IND-Enabling 1 2 3 Phase Estimated Annual US Addressable1 GENETIC CONDITIONS FGFR3ACH: TYRA-300 ~3K Potentially leading to additional skeletal dysplasias, including FGFR3-related conditions (HCH, SHOX), and

pediatric short stature ONCOLOGY ~9K ~40K ~5.5K FGFR3ONC: TYRA-300 FGFR4/3ONC: TYRA-430 FGFR2ONC: TYRA-200 TYRA retains an active FGFR3 discovery program. 1. Represents FGFR3/FGFR2/FGF19+ incidence and relapses for TYRA300/200/430, prevalence for

ACH Data from FGFR3ONC Anticipated Milestone Initiate Ph 2 study Further QD dose optimization Complete Ph1 Dose first patient

SAFETY ACTIVITY PK/PD On par with

erdafitinib label in FGFR3+ mUC patients at active dose levels TYRA-300 is the world's first oral, selective FGFR3 inhibitor with the potential to deliver benefit to cancer patients with a tolerable safety profile BENCHMARK1 READOUT 54.5%

(6/11) confirmed PRs vs. 35.3% ORR erdafitinib label 1. This comparison is solely based on BALVERSA (erdafitinib) prescribing information as of January 2024 and not based on any head-to-head clinical trials. Cross-study comparisons are

inherently limited and may suggest misleading similarities and differences. The values shown in the cross-study comparisons are directional and may not be directly comparable.

SAFETY ACTIVITY PK/PD On par with

erdafitinib label in FGFR3+ mUC patients at active dose levels Dose-dependent activity TYRA-300 is the world's first oral, selective FGFR3 inhibitor with the potential to deliver benefit to cancer patients with a tolerable safety profile

Anti-tumor activity observed in all FGFR3+ mUC 90 mg QD BENCHMARK1 READOUT 54.5% (6/11) confirmed PRs vs. 35.3% ORR erdafitinib label 1. This comparison is solely based on BALVERSA (erdafitinib) prescribing information as of January

2024 and not based on any head-to-head clinical trials. Cross-study comparisons are inherently limited and may suggest misleading similarities and differences. The values shown in the cross-study comparisons are directional and may not be directly

SAFETY ACTIVITY PK/PD On par with

erdafitinib label in FGFR3+ mUC patients at active dose levels Dose-dependent activity Safety profile with improved tolerability in FGFR1/2/4-driven toxicities compared to pan-FGFRis TYRA-300 is the world's first oral, selective FGFR3

inhibitor with the potential to deliver benefit to cancer patients with a tolerable safety profile Anti-tumor activity observed in all FGFR3+ mUC 90 mg QD Generally well-tolerated with infrequent FGFR2- and FGFR1-associated toxicities

BENCHMARK1 READOUT 54.5% (6/11) confirmed PRs vs. 35.3% ORR erdafitinib label 1. This comparison is solely based on BALVERSA (erdafitinib) prescribing information as of January 2024 and not based on any head-to-head clinical trials.

Cross-study comparisons are inherently limited and may suggest misleading similarities and differences. The values shown in the cross-study comparisons are directional and may not be directly comparable.

INTERIM PHASE 1 RESULTS ENA

Cysteine Mutations CC S249C R248C

Y373C G370C P P Fusions TACC3 (example) FGFR3 oncogenic alterations are common in bladder cancer Abbreviations: IR, Intermediate Risk; HR, High Risk 1. Weickhardt 2022 2. Mayr, 2022; Kacew, 2020; Knowles, 2020 3. BALVERSA (erdafitinib)

prescribing information 01/2024; BLC3001 Cohort 1 trial data 4. Daneshmand, 2023 (SUO) 5. Catto, 2023 (SUO) 6. Lyou, 2022 7. Cha, 2020 (ASCO GU) 8. Necchi, 2023; represents ORR for continuous dosing cohort P FGFR3 P FGFR3+ (constitutively

Cysteine Mutations CC S249C R248C

Y373C G370C P P Fusions TACC3 (example) FGFR3 oncogenic alterations are common in bladder cancer Abbreviations: IR, Intermediate Risk; HR, High Risk 1. Weickhardt 2022 2. Mayr, 2022; Kacew, 2020; Knowles, 2020 3. BALVERSA (erdafitinib)

prescribing information 01/2024; BLC3001 Cohort 1 trial data 4. Daneshmand, 2023 (SUO) 5. Catto, 2023 (SUO) 6. Lyou, 2022 7. Cha, 2020 (ASCO GU) 8. Necchi, 2023; represents ORR for continuous dosing cohort P FGFR3 P FGFR3+ (constitutively active)

mUC FGFR3+ Oral erdafitinib 10 20%1 35.3% ORR, 12.1mo OS3 (n=136) pemigatinib infigratinib 23% ORR8 (n=103) 24% ORR6 (n=54)

Cysteine Mutations CC S249C R248C

Y373C G370C P P Fusions TACC3 (example) FGFR3 oncogenic alterations are common in bladder cancer Abbreviations: IR, Intermediate Risk; HR, High Risk 1. Weickhardt 2022 2. Mayr, 2022; Kacew, 2020; Knowles, 2020 3. BALVERSA (erdafitinib)

prescribing information 01/2024; BLC3001 Cohort 1 trial data 4. Daneshmand, 2023 (SUO) 5. Catto, 2023 (SUO) 6. Lyou, 2022 7. Cha, 2020 (ASCO GU) 8. Necchi, 2023; represents ORR for continuous dosing cohort P FGFR3 P FGFR3+ (constitutively active)

mUC FGFR3+ Oral erdafitinib 10 20%1 35.3% ORR, 12.1mo OS3 (n=136) pemigatinib infigratinib 23% ORR8 (n=103) 24% ORR6 (n=54) NMIBC 40 80%2 IR: 83% CR4 (n=18) HR(Cis): 73% CR5 (n=11) HR (Pap): 75% CR7 (n=4)

Pan FGFR inhibition is associated

with key on-target toxicities Nail disorders Stomatitis Dry mouth PPE Dry eye Central serous retinopathy Diarrhea ALT increase AST increase Dry skin Hyperphosphatemia Adverse reactions in 15% of patients who received erdafitinib (n=135)1,#

FGFR2 RELATED FGFR1 RELATED OTHER AEs Grade 3 Grade 1 2 1Adapted from: Erdafitinib tablets, for oral use. Prescribing information 01/2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Accessed 06

October 2024. 2Lacouture ME et al. Oncologist. 2021. 3Subbiah V, Verstovsek S. Cell Rep Med. 2023. 4Kommalapati A, et al. Cancers. 2021. #Study BLC3001 2,3 3,4

Adverse reactions have occurred

requiring dosage modifications of erdafitinib 1. BALVERSA (erdafitinib) prescribing information 01/2024, BLC3001 Cohort 1 data. Adverse reactions leading to dosage interruptions or reductions of erdafitinib in >4% of patients. Nail disorders 22

Stomatitis 19 Eye disorders 16 PPE 15 Diarrhea 10 Hyperphosphatemia 7 Increased AST 6 Increased ALT 5 Nail disorders 27 Stomatitis 19 Eye disorders 17 PPE 12 Diarrhea 7 Dry mouth 4.4 Hyperphosphatemia 4.4 DISCONTINUATION INTERRUPTION REDUCTION 14%

72% 69% Adverse reactions resulting in dose adjustments in patients who received erdafitinib (n=135)1

TYRA-300 is a potential

first-in-class, highly selective FGFR3 inhibitor All experiments conducted under identical conditions, tested in duplicate. 0 20 40 60 80 120 Selectivity observed for TYRA-300 vs. approved or late-stage clinical compounds: in vitro Ba/F3 Cellular

IC50 (nM) FGFR1 FGFR2 FGFR3 FGFR4 P F E I T P F E I T P E I P F E I T 459 142 F T T TYRA-300 I infigratinib erdafitinib E pemigatinib P futibatinib F 100 19x 63x 55x FGFR1 4.2x 4.9x 2.4x 2.2x FGFR2 1.4x 1.3x 0.8x 0.8x FGFR4 14x 7.6x 27x 67x I P F E

Our Phase 1 explored QD* dose

escalation and expansion Dose QD* Illustrative Dose QD PART A (all comers) PART B (FGFR3+ only) Dose Escalation Dose Expansion *1x daily All solid tumor types1 FGFR+/- Solid tumors with focus on mUC1 FGFR3+ only 1. Previously treated patients,

including FGFRi, allowed

We dose escalated to 120mg QD and

then expanded up to 90mg Dose QD* 10mg 20mg 40mg 60mg Illustrative Dose QD 40mg 60mg PART A (all comers) PART B (FGFR3+only) 90mg RP2D Dose Escalation Dose Expansion 120mg 1 1 3 3 7 7 10 5 4 90mg N= N= *1x daily

The study population was older and

heavily pre-treated mUC 25 (61) Lung 3 (7) Head and Neck 4 (10) Other 9 (22) Mutation 17 (41) Fusion 15 (37) None 10 (24) 0 5 (12) 1 7 (17) 2 11 (27) 3 18 (44) TUMOR TYPE FGFR3 ALTERATION PRIOR LINES OF THERAPY n=41 (range 34 84) 66

(yrs) MEDIAN AGE SEX AT BIRTH ECOG PS Male 30 (73) n (%) 0 14 (34) 1 27 (66) n (%) Abbreviations: mUC, metastatic urothelial cancer Safety analysis set, n=41

The study population was older and

heavily pre-treated mUC 25 (61) Lung 3 (7) Head and Neck 4 (10) Other 9 (22) Mutation 17 (41) Fusion 15 (37) None 10 (24) 0 5 (12) 1 7 (17) 2 11 (27) 3 18 (44) TUMOR TYPE FGFR3 ALTERATION PRIOR LINES OF THERAPY n=41 (range 34 84) 66

(yrs) MEDIAN AGE SEX AT BIRTH ECOG PS Male 30 (73) n (%) 0 14 (34) 1 27 (66) n (%) Abbreviations: mUC, metastatic urothelial cancer Safety analysis set, n=41 76% of mUC patients had 3 prior lines of therapy

Preliminary data suggests TYRA-300

is generally well tolerated Any Grade Grade 3 Any TRAEs, n (%) 32 (78) 8 (20) TRAEs in >10% of participants, n(%) ALT increase# 10 (24) 2 (5) Diarrhea* 9 (22) 1 (2) Dry mouth 9 (22) AST increase 8 (20) 1 (2) Dry skin 6 (15) Fatigue 5 (12)

#Drug-related discontinuation, Grade 3 ALT elevation 90 mg QD; *DLT, Grade 3 diarrhea 90 mg QD Abbreviations: TRAE, treatment-related adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; DLT, dose-limiting toxicity; SAE,

serious adverse event Safety analysis set, n=41 n=41 1 DLT 90 mg QD, Gr. 3 diarrhea* 1 Drug-related discontinuation 90 mg QD, Gr. 3 ALT elevation# 4 Related SAEs Related to TYRA-300 0 Grade 4 SAE No drug-related events leading to

Minimal changes in phosphate at

90 mg QD observed Minimal impact in phosphate at 90 mg QD. Dashed lines denote 5.5 and 7 mg/dL used by Loriot et al. where 5.5- 6.9 mg/dL was defined as Grade 1 and 7.0-8.9 mg/dL as Grade 2. C1D15 Phosphate C2D1 Phosphate 2.0 1.5 1.0

0.5 40 60 90 120 40 60 90 120 mmol/L 2.0 3.0 4.0 5.0 6.0 7.0 mg/dL Dose (mg) Dose (mg) Phosphate binder was used to manage treatment-related hyperphosphatemia in one patient (90 mg QD).

Exposure at doses 90 mg

exceeded FGFR3 IC90 target coverage 10,000 1,000 TYRA300 Concentration (ng/ml) 100 10 1 10 mg 20 mg 40 mg 60 mg 90 mg 120 mg 0 6 12 18 24 Time (hr) FGFR1 (IC50) FGFR4 (IC50) FGFR3 (IC90) FGFR2 (IC50) 2.5x 2.4x 2.5x Dose (mg) N (C1D15) AUC (ng*h/mL)

120 3 23,578 90 13 10,300 60 8 4,360 40 10 2,270 20 1 1,830 10 1 91.5

Predicted exposure was achieved in

human doses 90 mg QD FGFR3+ UM-UC-14 Xenograft Individual Steady State AUCs in Patients Murine 18 mg/kg Vehicle Erda (12.5 mg/kg BID) TYRA-300 (18 mg/kg QD) Days Dose Group (mg QD) AUClast (ng/mL) Tumor Volume (mm3) Data on File.

Radiographic tumor response

assessment in all evaluable patients Best Percent Change from Baseline Efficacy-evaluable population (n=36) FGFR3 Mutation FGFR3 Fusion mUC NE# FGFR3+ mUC Others Abbreviations: BOR, best overall response; NE, non-evaluable; PR, partial response; SD,

stable disease; PD, progressive disease. N=36/41 evaluable patients. BOR by investigator-assessed by RECIST v1.1. Only confirmed PRs reported. #Participant discontinued due to non-compliance. *Dose-escalation from 40 mg QD to 60 mg QD prior to

response Starting Dose QD

40 90 60 90 40 60 90 10 40 40 120 40 120 90 40 40 60 60 20 60 60 40 60 90 90 90 90 90 90 40* 90 120 90 90 90 90

Anti-tumor activity observed in all